## Tutorial for Surrogate Endpoint Validation Using Joint modeling and Mediation Analysis

Quentin Le Coent<sup>1</sup>, Catherine Legrand<sup>2</sup>, and Virginie Rondeau<sup>3</sup>

<sup>1</sup>Bloomberg School of Public Healt, Johns Hopkins University <sup>2</sup>ISBA/LIDAM, UCLouvain

<sup>3</sup>Bordeaux Population Health Research Center, INSERM U1219, Université de Bordeaux

#### Summary

The use of valid surrogate endpoints is an important stake in clinical research to help reduce both the duration and cost of a clinical trial and speed up the evaluation of interesting treatments. Several methods have been proposed in the statistical literature to validate putative surrogate endpoints. Two main approaches have been proposed: the meta-analytic approach and the mediation analysis approach. The former uses data from metaanalyses to derive associations measures between the surrogate and the final endpoint at the individual and trial levels. The latter rather uses the proportion of the treatment effect on the final endpoint through the surrogate as a measure of surrogacy in a causal inference framework. Both approaches have remained separated as the meta-analytic approach does not estimate the treatment effect on the final endpoint through the surrogate while the mediation analysis approach have been limited to single-trial setting. However, these two approaches are complementary. In this work we propose an approach that combines the meta-analytic and mediation analysis approaches using joint modeling for surrogate validation. We focus on the cases where the final endpoint is a time-to-event endpoint (such as time-to-death) and the surrogate is either a time-to-event or a longitudinal biomarker. Two new joint models were proposed depending on the nature of the surrogate. These model are implemented in the R package frailtypack. We illustrate the developed approaches in three applications on real datasets in oncology.

## 1 Introduction

Given the continued development of new and more effective therapies in oncology, the use of standard (final) endpoints in clinical trials may affect the feasibility of these trials. For example, a significant increase in overall survival requires long-term follow-up of patients to ensure adequate statistical power and therefore increases the duration and cost of the trial. The use of surrogate endpoints is therefore a possible way to enable such otherwise unfeasible studies. Surrogate endpoints are intermediate endpoints measured earlier and/or more frequently than the final (true) endpoints that help reduce the duration and cost of a trial compared to final endpoints (Buyse et al. (2000)). The benefit of a surrogate endpoint is that is can be used as a primary endpoint in place of the final endpoint in a new clinical trial. However, the final endpoint being the "gold-standard", conclusions of treatment efficacy in a clinical trial based solely on its observed efficacy on the surrogate should be extendable to the final endpoint. Therefore, prior to any use in a new trial, a surrogate endpoint must have been carefully validated. This validation requires that both the final endpoint and the surrogate have been studied in previous studies. Several methods have been proposed in the last decades following the seminal paper of Prentice (PRENTICE,

1989). Since, two main approaches have been developed, one based on quantifying "associations" between the surrogate and the final endpoint and others based on identification of the proportion of treatment effects on the final endpoint through the surrogate (JOFFE and GREENE, 2009). The main developments of the "associations" approach is the meta-analytic approach (DANIELS and HUGHES, 1997; BUYSE et al., 2000) while the proportion of treatment effect has been developed in the mediation analysis setting (VANDENBERGHE et al., 2018; WEIR et al., 2022; PARAST, CAI, et al., 2017).

The meta-analytic approach uses data from meta-analyses of randomized clinical trials to derive and quantify the association between the surrogate and the final endpoint at two levels. At the individual level the association between the two endpoints is quantified while at the trial-level the association between the treatment effects on both endpoints across the trials is used. For the individual-level association, this approach relies on joint models for the two endpoints using individual (patient) level random effects. These random effects can be shared or correlated between the two endpoints and can be used to estimate an individual-level association between the surrogate and the final endpoint. For the trial-level association, methods based on one or two stages approaches have been developed. In the two-stage approaches, the joint model is estimated with fixed trialspecific treatment effects on the two endpoints. Then at the second stage the estimated treatment effects on the two endpoints for each trial can be regressed in a linear mixed model. The resulting coefficient of determination can then be used as trial-level measure of association between the treatment effects. However, these two stage approaches can be replaced by one stage approaches in which the fixed trial-specific treatment effects in the joint model are replaced by the sum of a fixed effect (not trial-specific) and a trial-level random effect for each endpoint. Then the elements of the covariance matrix of these trial-level random effects are used to derive the coefficient of determination between the treatment effects. Then, a surrogate endpoint will be claimed validated if the associations at both individual and trial levels are sufficiently large. The meta-analytic approach has been broadly studied and adapted to settings with different types of surrogate and final endpoint: continuous, binary, censored time-to-event (BURZYKOWSKI, BUYSE, and MOLENBERGHS, 2005). Another approach, less developed, focuses on identifying the pathways through which the treatment effect on the final endpoint goes. A natural surrogacy measure in that case is the proportion of treatment effect, defined as the ratio of the indirect treatment effect on the final endpoint through the surrogate over the total treatment effect on the final endpoint. Early developments of this approach were based on estimating regression coefficients of the treatment effect in a model for the final endpoint adjusted only on the treatment arm and a model adjusting on both the treatment and the surrogate (PRENTICE, 1989; FREEDMAN et al., 1992). Then the ratio of the estimated regression coefficient associated with the treatment in the second model over the coefficient estimated in the first model was taken as a measure of the proportion of treatment effect. However, this approach lacks causal interpretability since adjusting on a posttreatment covariate affected by the treatment (the surrogate) may yield biased estimation of the treatment effect by neglecting potential confounding between the surrogate and the final endpoint (ROSENBAUM, 1984; ROBINS, 1986; FRANGAKIS and RUBIN, 2002). Moreover, using estimated regression coefficients to define a proportion of treatment effect complicates the interpretation of this proportion on different scales. For example, a high proportion using estimated coefficients in a Cox model might not translates in the same proportion on the survival scale (i.e. by using the difference of survival rates as a measure of the treatment effect). Additionally, estimates of hazard models may also suffer from a lack of causal interpretability in contrary to survival measures (HERNÁN, 2010). Therefore, methods based on causal mediation analysis have been developed. These methods often rely on the causal framework of potential outcomes (HOLLAND, 1986). The benefit of using causal mediation analysis is two fold: first it does not suffer from a lack of causal interpretability; second, it gives model-free definitions of "treatment effects", which can be defined in a broad variety of situations. For example, if we are interested in the case where the final endpoint is a time-toevent, then it is possible to give a definition of the proportion of treatment effects on the survival scale. However, causal mediation analysis comes at a price: one often needs to rely on strong identifiability assumptions (IMAI et al., 2010) and the estimations of the quantities of interest are generally more complex than simply fitting a regression model. Less developments of the mediation analysis for surrogate endpoints validation have been made compared to the meta-analytic approach. One limitation of the mediation analysis is that it is often limited to single-trial data, which may complicate the generalization of its results.

We propose a novel development that combines the meta-analytic and mediation analysis approaches. We focus on the specific case where the final endpoint is a time-to-event. We develop two joint models for the case where the surrogate is also a time-to-event or a continuous longitudinal biomarker. The first model is an extension of the joint model proposed by SOFEU et al. (2019) that allows for a potential mediated treatment effect on the final endpoint through the surrogate. The second model is a joint model for a time-to-event and a longitudinal surrogate. In both models the use of individual and trial-level random effects allows for i) using meta-analytic data and ii) deriving individual and trial-level associations. From these models we also gave a causal definition of the indirect treatment effect on the final endpoint through the surrogate and the direct treatment effect using mediation analysis. The use of random effects allows us to make less stringent identifiability assumptions than often found in the mediation analysis literature.

This paper is organized as follows. In the first Section we provide a review on the existing R packages available on the CRAN for surrogate endpoints validation with their principal options (type of endpoints, methodology etc.). In a second section we introduce the statistical methodology for surrogate endpoint validation. Two joint models are presented, the first one for the case where the surrogate endpoint is a time-to-event and the second where the surrogate is a longitudinal continuous biomarker. In both models the final endpoint will be a time-to-event. We also present the measures of surrogacy resulting from these models. In the third Section we present two functions implemented in frailtypack, jointSurroPenal and longiPenal, dedicated to each proposed model. We present the main arguments of these functions and their role. In the fourth section we provide three illustrations of the proposed models on real-data examples in oncology. Finally in the fifth section we conclude and provide some further developments.

## 2 Existing R packages for surrogate validation

In this Section we review some R packages which provide useful measures for surrogate endpoint validation.

The package **Rsurrogate** provides several functions to compute the proportion of treatment effect on a final endpoint through a surrogate. It can be used with a censored time-to-event final endpoint and a surrogate measured at a specific time, with the surrogate being treated as missing if the final endpoint occurs before this time point. It can also be used to compute the proportion of treatment effect on a (time-to-event) final endpoint through several surrogates. It further provides a function to compute this proportion in the case where the final endpoint is a continuous endpoint, where a function to correct for a potential measurement error in the surrogate is also available. In all cases the surrogate (or vector of surrogates) is assumed to be continuous (PARAST, 2021a).

The package SurrogateOutcome provides a function to estimate the proportion of treatment effect on a timeto-event endpoint through a time-to-event surrogate observed up to a landmark time (PARAST, 2021b). These effects are defined as differences in restricted mean survival times. This package also provides a function in which the surrogate is replaced by the final endpoint itself observed up to this landmark time. The package longsurr provide a function to compute the proportion of treatment effect on a final continuous endpoint through a longitudinal surrogate, where it is assumed that each patient has the same number of repeated observations of the surrogate (and that each measurement is taken at the same time) (PARAST and AGNIEL, 2022). The package surrogate (VAN DER ELST et al., 2022) is the most developed package dedicated to surrogate endpoint validation available on the CRAN. It provides numerous functions to assess surrogacy depending on the nature of the surrogate and the final endpoint based on the meta-analytic, information-theoretic, and causal-inference frameworks. For example, this package can be used to assess the trial-level surrogacy for two time-to-event endpoints using a two-stage approach or based on information theory and a two-stage approach. It can also be used to estimate the trial-level surrogacy by providing directly the coefficients associated with the estimated treatment effects on the final and surrogate endpoints. It also provides a function to evaluate surrogacy following Prentice's criteria in a single-trial setting with two continuous endpoints. Although we succinctly presented packages developed in R, implementations for surrogate validation have also been proposed in other softwares such as SAS (ALONSO et al., 2016). None of those packages combined the one-step meta-analytic approach with the mediation analysis. We propose an R package to validate a longitudinal biomarker or failure time as a surrogate of a time-to-event using mediation analysis and the meta-analytic approach.

## 3 Methods: surrogate validation using joint modeling and mediation analysis

In this Section we introduce the two main models: the first one for a time-to-event surrogate and the second one for a longitudinal surrogate. The surrogacy evaluation criteria are presented for both the meta-analytic and the mediation approaches. Estimation method of model parameters is also presented.

## 3.1 Models and estimation

In a setting of meta-analytic data with K trials, let *i* denotes the *i*th trial and *ij* the *j*th subject from trial *i*,  $j = 1, ..., n_i$ . The treatment and covariates are denoted by  $Z_{ij}$  and  $X_{ij}$ .

## 3.1.1 Time-to-event surrogate

Let  $T_{ij}$  and  $S_{ij}$  be the final endpoint and the surrogate endpoint respectively. Let  $C_{ij}$  denotes the censoring time. We assume a semi-competing risks setting in that  $S_{ij}$  can be censored by  $T_{ij}$  but not the opposite. The observed outcomes are therefore  $T_{ij}^* = \min(T_{ij}, S_{ij}), \, \delta_{ij} = \mathbb{1}_{T_{ij} \leq C_{ij}}, \, S_{ij}^* = \min(S_{ij}, T_{ij}^*)$  and  $d_{ij} = \mathbb{1}_{S_{ij} \leq T_{ij}^*}$ . The joint model is given by (LE COËNT et al., 2022):

$$\begin{pmatrix}
\lambda_{S} (t \mid \omega_{ij}, u_{i}, \nu_{S,i}, Z_{ij}, X_{ij}) = \lambda_{0,S}(t) \exp\left(\omega_{ij} + u_{i} + Z_{ij}(\nu_{S,i} + \beta_{Z,S}) + \beta'_{S} X_{ij}\right) \\
\lambda_{T} (t \mid \omega_{ij}, u_{i}, \nu_{T,i}, Z_{ij}, S_{ij}, X_{ij}) = \lambda_{0,T}(t) \exp\left(\zeta \omega_{ij} + \alpha u_{i} + Z_{ij}(\nu_{T,i} + \beta_{Z,T}) + \beta'_{T} X_{ij} + \gamma(S_{ij})I(S_{ij} \leq t)\right).$$
(1)

In this model,  $\omega_{ij}$  and  $u_i$  are individual and trial level random effects respectively used to take into account the heterogeneity between patients at the individual and trial levels. The trial-level random effects ( $\nu_{S,i}, \nu_{T,i}$ ) take into account a potential heterogeneity between treatment effects across trials. All of these random effects are assumed to be Gaussian:

$$\omega_{ij} \sim \mathcal{N}(0, \theta^2)$$
$$u_i \sim \mathcal{N}(0, \gamma^2)$$
$$(\nu_{S,i}, \nu_{T,i})' \sim \mathcal{N}(0, \Sigma_{\nu})$$

The parameters  $(\zeta, \alpha)$  are power parameters allowing the random effects  $\omega_{ij}$  and  $u_i$  to affect the hazard functions of S and T differently. Parameters  $\beta_{Z,S}$  and  $\beta_{Z,T}$  are the fixed treatment effects on the surrogate and the final endpoint respectively. The functions  $\lambda_{0,T}$  and  $\lambda_{0,S}$  are the baseline hazard functions for the two endpoints.

In model (1), the term  $\gamma(S_{ij})I(S_{ij} \leq t)$  corresponds to a direct link of the surrogate on the final endpoint. This link can be interpreted as a modification of the hazard function of  $T_{ij}$  at the time of occurrence of  $S_{ij}$  whose magnitude is given by the function  $\gamma(\cdot)$ . From a mediation perspective this term is important as without it the two endpoints would be independent given the random effects, treatment and covariates, hence no direct effect of the surrogate on the final endpoint would be possible (which corresponds to removing the arrow between S and T in Figure 1(b)).

Outside this mediation perspective, and based only on the meta-analytic approach, a direct link between S and T is not required, and a joint model without the term  $\gamma(S_{ij})I(S_{ij} \leq t)$  can be used (SOFEU et al., 2019).

## 3.1.2 Longitudinal surrogate

Let  $M_{ij}$  denotes the surrogate which is a continuous longitudinal biomarker (repeated measures over time) and  $T_{ij}$  is a time-to-event defined as previously. For subject ij we observe  $\tilde{M}_{ij} = {\tilde{M}_{ij}(t_{ijk}), 1 \leq k \leq n_{ij}}$  the longitudinal biomarker measured with an error. where  $n_i ij$  is the number of repeated measurements of subject ij.

The proposed joint model is given by,

$$\begin{cases} \tilde{M}_{ij}(t) = \theta'_{ij}f(t) + \beta'_M X^M_{ij}(t) + (\beta_{Z,M} + \nu_{M,i})Z_{ij} + \varepsilon_{ij}(t) \\ \lambda_{ij}(t) = \lambda_0(t) \exp\left((\beta_{Z,T} + \nu_{T,i})Z_{ij} + \beta'_T X^T_{ij}(t) + \eta' h(M_{ij})\right) \end{cases}$$
(2)

where  $M_{ij}(t) = \theta'_{ij}f(t) + \beta'_M X^M_{ij}(t) + (\beta_{Z,M} + \nu_{M,i})z$  is the true, error-free, marker and  $\varepsilon_{ij}(t) \sim \mathcal{N}(0, \sigma_{\varepsilon}^2)$ (the independent measurement error).

As in Model (1), the random effects  $(\nu_{S,i}, \nu_{T,i})$  are trial-level effects taking into account the heterogeneity of the treatment effect across trial and are assumed to be jointly Gaussian:  $(\nu_{M,i}, \nu_{T,i})' \sim \mathcal{N}(0, \Sigma_{\nu})$ . The function f(t) is a vector that represents the temporal evolution of the biomarker and may be composed of several components. The vector  $\theta$  is the sum of fixed effects and individual random-effects associated with each component of f(t),  $\theta_{ij} = \beta + \omega_{ij}$ . For example if f(t) = (1, t)' then  $\theta_{ij} = (\beta_0 + \omega_{ij0}, \beta_1 + \omega_{ij1})'$ . The vector  $\omega_{ij}$ is assumed to be Gaussian with mean 0 and unstructured covariance matrix D,  $\omega \sim \mathcal{N}(0, D)$ .

In Model (2), the two submodels are linked together through the "link" function  $h(M_{ij})$ . This function represents the association structure between the longitudinal surrogate and the final endpoint. The strength of this association is taken into account through the "association parameter"  $\eta$ . This parameter quantifies the magnitude of the dependence between both outcomes. The most common link functions found in the literature are the following (RIZOPOULOS, 2012b):

- The "current level" link:  $h(M_{ij}) = M_{ij}(t)$ . This is probably the most natural link between the biomarker and the time-to-event that assumes that the risk of occurrence of T at any time t depends only on the current value of the biomarker at that time.
- The "current slope" link:  $h(M_{ij}) = \frac{dM_{ij}(t)}{dt}$ . Rather than considering an association between the hazard function of T with the current value of  $M_{ij}$  at time t, we consider an association with the increase (or decrease) of  $M_{ij}$  at time t.
- $h(M_{ij}) = \omega_{ij}$ , the "shared random-effects" link function. As it is time-independent, it assumes that dependence structure between the two outcomes is constant over time regardless of the biomarker evolution.

From a mediation viewpoint, in order to enable a potential mediated treatment effect on the final endpoint through the surrogate, the quantity in the link function must depends on the treatment value (which corresponds to the arrow from Z to h(M) in Figure 1(c)). For example in the "current-slope" case the slope must be dependent on the treatment. This can be achieved by adding an interaction between treatment and time in the longitudinal model. Moreover, the shared random-effects link is not relevant in a mediation analysis perspective as the random effects are assumed independent of the covariates.



Figure 1: Directed acyclic graph associated with the joints models: (a) in a general case, (b) for a time-to-event surrogate as represented by Model (1) and (c) for a longitudinal surrogate (Model (2)). Here  $\xi$  denotes the vector of all the random effects in models 1 and 2.

### 3.1.3 Likelihoods and estimations

Both Model (1) and Model (2) can be estimated through maximum likelihood. The baseline hazard functions can be estimated parametrically using M-splines which provides flexibility in their estimations. A penalized likelihood can be maximized instead of the full likelihood to ensure smooth estimate of these functions (JOLY et al., 1998; RONDEAU, MATHOULIN-PELISSIER, et al., 2007). Let  $\phi_1$  and  $\phi_2$  be the vectors of all the parameters in Model (1) and Model (2) respectively. The penalized likelihood for Model (1) is given by:

$$L_{\rm pen}(\phi_1) = L(\phi_1) - \kappa_T \int_0^\infty \left(\lambda_{0,T}^{\prime\prime}(t)\right)^2 \mathrm{d}t - \kappa_S \int_0^\infty \left(\lambda_{0,S}^{\prime\prime}(t)\right)^2 \mathrm{d}t \tag{3}$$

and for the Model (2):

$$L_{\text{pen}}(\phi_2) = L(\phi_2) - \kappa_T \int_0^\infty \left(\lambda_{0,T}''(t)\right)^2 \mathrm{d}t \tag{4}$$

In these equations, the terms  $\kappa_S$  and  $\kappa_T$  are penalization terms on the second derivatives of the baseline hazard functions that ensure smooth estimations of these functions.

In practice the maximization of the penalized likelihood is carried out using the Levenberg-Marquardt algorithm (MARQUARDT, 1963).

## 3.2 Surrogacy measures

In this section we provide definitions and formulas for the surrogacy measures that can be used with each model. In the meta-analytic approach, several measures have been proposed in the literature: individual and triallevel associations and the surrogate threshold effect (STE). From a mediation perspective the main measure of surrogacy is the proportion of treatment effect (PTE), which quantifies the amount of treatment effect on the final endpoint going through its effect on the surrogate. In the following we present each of these measures. We denote by  $\xi$  the vector of all random effects in Model (1) or Model (2).

#### 3.2.1 Individual-level association

Individual-level surrogacy is often represented by a measure of association between the surrogate and the final endpoint, with the Kendall's  $\tau$  between both endpoints being commonly used. We first introduce the definition of the Kendall's  $\tau$  and then give a derivation based on the two proposed joint models. Let X and Y be two continuous random variables. For two random subjects  $(X_1, Y_1)$  and  $(X_2, Y_2)$ , Kendall's  $\tau$  is defined as the probability that the two couples  $(X_1, Y_1)$  and  $(X_2, Y_2)$  are concordant minus the probability that they are discordant. The couples are concordant if  $X_1 > X_2$  and  $T_1 > T_2$  or if  $X_1 < X_2$  and  $T_1 < T_2$  which is equivalent to  $(X_1 - X_2)(Y_1 - Y_2) > 0$ . They are discordant otherwise. Therefore the Kendall's  $\tau$  for (X, Y) can be written as (WANG and WELLS, 2000)

$$\tau = 4\mathbb{P}\left(X_1 > X_2, Y_1 > Y_2\right) - 1.$$
(5)

In the case where X and Y are independent,  $\mathbb{P}((X_1 > X_2, Y_1 > Y_2) = \mathbb{P}(X_1 > X_2) \mathbb{P}(Y_1 > Y_2)$  and by symmetry  $\mathbb{P}(X_1 > X_2) = \mathbb{P}(Y_1 > Y_2) = \frac{1}{2}$  which gives  $\tau = 0$ . On the other hand, for perfect correlation X = Y,  $\mathbb{P}(X_1 > X_2, Y_1 > Y_2) = \mathbb{P}(X_1 > X_2) = \frac{1}{2}$  and then  $\tau = 1$  while  $X = -Y \Rightarrow \mathbb{P}(X_1 > X_2, Y_1 > Y_2) = 0 \Rightarrow \tau = -1$ . Hence,  $\tau$  takes values in [-1, 1] with values close to 0 meaning small association between X and Y.

#### (a) Kendall's $\tau$ for a time-to-event surrogate

For Model (1) the Kendall's  $\tau$  is equal to (for the variables S and T),

$$\tau = 4 \int_{\mathbb{R}^4} \left[ \int_0^\infty \int_0^\infty \left( \int_0^\infty \mathbb{P}(T_1 > t \mid S_1 = s + \alpha, \xi_1) f_{T_2}(t \mid S_2 = s, \xi_2) \mathrm{d}t \right) \\ \times f_{S_1}(s + \alpha \mid \xi_1) f_{S_2}(s \mid \xi_2) \mathrm{d}s \mathrm{d}\alpha \right] \mathbb{P}(S_1 > S_2 \mid \xi_1, \xi_2) \mathrm{d}f(\xi_1, \xi_2) \xi_1 \mathrm{d}\xi_2 - 1.$$
(6)

In the case where there is no effect of S on T (i.e. independence between S and T given the random effects or  $\gamma(S) = 0$ ), this expression reduces to

$$\tau = \int_{\mathbb{R}^4} \left[ \frac{e^{\omega_2 + u_2} + e^{\zeta \omega_2 + \alpha u_2}}{(e^{\omega_1 + u_1} + e^{\omega_2 + u_2}) (e^{\zeta \omega_1 + \alpha u_1} + e^{\zeta \omega_2 + \alpha u_2})} \right]$$

$$\frac{1}{4\pi^2 \theta \gamma} \exp\left( -\frac{1}{2} \left( \frac{\omega_1 + \omega_2}{\theta^2} + \frac{u_1 + u_2}{\gamma^2} \right) \right) d\omega_1 d\omega_1 du_1 du_2.$$
(7)

which can be easily approximated using Monte Carlo sampling (SOFEU et al., 2019).

## 3.2.2 Trial-level association

For both Model (1) and Model (2), the trial-level association is defined as the coefficient of determination of the random effects ( $\nu_S, \nu_T$ ) or ( $\nu_M, \nu_T$ ). For both models these random effects are assumed to be Gaussian with mean 0 and covariance matrix  $\Sigma_{\nu}$ . If we write,

$$\Sigma_{\nu} = \begin{pmatrix} \sigma_{\nu_1}^2 & \sigma_{\nu_{12}} \\ \sigma_{\nu_{12}} & \sigma_{\nu_2}^2 \end{pmatrix}.$$

Then, the trial-level measure of surrogacy,  $R_{\text{trial}}^2$  is defined as:

$$R_{\rm trial}^2 = \frac{\sigma_{\nu_{12}}^2}{\sigma_{\nu_1}^2 \sigma_{\nu_2}^2}.$$

As for the Kendall's  $\tau$ , standard error for the estimator of  $\hat{R}^2_{\text{trial}}$  can be obtained using parametric bootstrap. However, the simple form of  $R^2_{\text{trial}}$  allows the derivation of an estimator of its standard error directly from the estimated covariance matrix of the vector of parameter using the delta-method and then using the normal approximation to derive a confidence interval. However the later could yield confidence intervals that exceeds the range [0, 1] of  $R^2_{\text{trial}}$ .

### 3.2.3 Surrogate threshold effect

The surrogate threshold effect is the smallest treatment effect on the surrogate endpoint required to yield a significant effect on the final endpoint (BURZYKOWSKI and BUYSE, 2006).

The prediction interval for the treatment effect on the final endpoint in a new trial  $i_0$ ,  $\beta_{Z,T} + \nu_{T,i_0}$ , given that the observed effect on the surrogate is  $\beta_{Z,S} + \nu_{S,i_0}$  is:

$$\mathbb{E}\left(\beta_{Z,T} + \nu_{T,i_0} \mid \nu_{S,i_0}\right) \pm z_{1-\gamma/2} \sqrt{\mathbb{V}\left(\beta_{Z,T} + \nu_{T,i_0} \mid \nu_{S,i_0}\right)}$$

where  $z_{1-\gamma/2}$  is the  $(1-\gamma/2)$  percentile of the standard normal distribution. In order to predict a significant effect of the treatment on the final endpoint, the lower bound of this interval should be greater than 0 (or the upper bound lower than 0 depending on the type of effect one is interested in). This interval only depends on  $\nu_{S,i_0}$ . Let  $l(\nu_{S,i_0})$  be the lower bound of this interval, then the STE is the value of  $\nu_{S,i_0}$  such that

$$l(\nu_{S,i_0}) = 0$$

### **3.2.4** Proportion of treatment effect

The PTE is a measure related to mediation analysis. Mediation analysis investigates how the total effect of a treatment on a outcome can be decomposed as a direct effect and an indirect effect through a mediator (intermediate variable). Most development of mediation analysis have been made in the realm of causal inference, mostly based on counterfactual outcomes. In our case, the mediator is the surrogate endpoint of interest and the endpoint is the final endpoint. Let,

$$\mathbb{S}^{zz'}(t) = \mathbb{P}(T(z, S(z') > t)),$$

be the survival function of the final endpoint T if the treatment for T is set to z but to z' for the surrogate S (here we do not make a distinction between a time-to-event surrogate or a longitudinal surrogate). Details on the interpretations of the above formula have been published LE COËNT et al., 2022.

For a binary treatment we can derive its natural indirect effect (NIE) on T through S as:

$$\operatorname{NIE}(t) = \mathbb{S}^{11}(t) - \mathbb{S}^{10}(t).$$

The righthand side of this formula is the difference between the survival function of T in the case where the treatment is set to 1 for both S and T and the survival function of T in the case where the treatment is set to 1 for T but to 0 for S. The only difference between  $\mathbb{S}^{11}(t)$  and  $\mathbb{S}^{10}(t)$  is the treatment value for S, hence their difference quantifies the amount of treatment effect (on the survival scale) on T due to its effect on S. In the same manner we can define the natural direct effect as:

$$NDE(t) = S^{10}(t) - S^{00}(t)$$

The total treatment effect (TE) is then the sum of the NIE and NDE, TTE(t) = NIE(t) + NDE(t). Finally, the measure of surrogacy is defined as:

$$PTE(t) = \frac{NIE(t)}{TTE(t)} = \frac{S^{11}(t) - S^{10}(t)}{S^{11}(t) - S^{00}(t)}.$$
(8)

which is the proportion of treatment effect going through the surrogate. To be able to compute the function PTE(t) we need to compute the functions  $S^{zz'}(t)$ , which can be done from Model (1) and Model (2) using the formula (LE COËNT et al., 2022; ZHENG and LIU, 2021),

$$\mathbb{S}^{zz'}(t) = \int_{\mathcal{X}} \int_{0}^{\infty} \int_{\xi} \mathcal{S}_{T}(t \mid s, z, \xi, X = x) f_{S}(s \mid z', \xi, x) f_{\xi}(\xi) f_{X}(x) \mathrm{d}s \mathrm{d}\xi \mathrm{d}x \quad \text{for Model (1)}$$

$$\mathbb{S}^{zz'}(t) = \int_{\mathcal{X}} \int_{\xi} \mathcal{S}_{T}\left(t \mid h(M^{z'}), \xi, z, x\right) f_{\xi}(\xi) f_{X}(x) \mathrm{d}\xi \mathrm{d}x \quad \text{for Model (2)},$$
(9)

where  $f_{\xi}(\cdot)$  and  $f_X(\cdot)$  are the density functions of the random-effects and covariates in the models respectively. In the first equation,  $S_T(t \mid s, z', \xi, x)$  is the survival function of T evaluated at t, given the treatment is set to z, the surrogate S = s, the random effects  $\xi$  and covariates x. The function  $f_S(s \mid z, \xi, x)$  is the density of S given the treatment is set to Z = z', the random effect and covariates. In the second equation,  $S_T\left(t \mid h(M^{z'}), \xi, Z = z, X = x\right)$  is the survival function of T given the treatment Z = z, the random effects x, the covariates x and the link function  $h(M^{z'})$  given the treatment for M is set to z'. Note that in the second case, in contrary to the first case, we do not need to integrate over the distribution of  $M^{z'}$  since it only depends on z', the random effects  $\xi$ , and the covariates x. From Equation 9, PTE(t) can be obtained by setting the appropriate values for z and z' following Equation 8. All the functions involved in the righthand side of Equation 9 can be derived from the estimated parameters of the model, except  $f_X(\cdot)$  for which averaging over the observed distribution of the covariates in the dataset can be used to approximate the integral over  $\mathcal{X}$ . As for the Kendall's  $\tau$  and  $R_{\text{trial}}^2$ , the standard error and confidence interval of PTE(t) can be obtained through parametric bootstrap.

## 3.3 Implementation in frailtypack

In this Section we present two main functions of the **frailtypack** package for investigating surrogacy and their main arguments. A detailed explanation of these functions can be found in the reference manual of the package available in R or on the CRAN (RONDEAU and GONZALEZ, 2005). In this article we use **frailtypack** version 3.6.5 and R version 4.4.0.

## 3.3.1 Function jointSurroPenal

The function jointSurroPenal can be used to investigate surrogacy when both the surrogate S and the final endpoint T are time-to-event (model (1)). The call to this function is as follows (the values given for each parameters are the default values):

```
R> model<- jointSurroPenal(data, maxit = 50,
```

```
indicator.zeta = 1, indicator.alpha = 1,
+
           frail.base = 1, n.knots = 6, LIMparam = 0.001,
+
           LIMlogl = 0.001, LIMderiv = 0.001, nb.mc = 300,
+
+
           nb.gh = 32, nb.gh2 = 20, adaptatif = 0, int.method = 2,
           nb.iterPGH = 5, nb.MC.kendall = 10000, nboot.kendall = 1000,
+
+
           true.init.val = 0, theta.init = 1, sigma.ss.init = 0.5,
           sigma.tt.init = 0.5, sigma.st.init = 0.48,
+
+
           gamma.init = 0.5, alpha.init = 1,
+
           zeta.init = 1, betas.init = 0.5, betat.init = 0.5,
+
           scale = 1, random.generator = 1, kappa.use = 4,
+
           random = 0, random.nb.sim = 0,
           seed = 0, init.kappa = NULL,
+
           ckappa = c(0,0), nb.decimal = 4,
+
+
           print.times = TRUE, print.iter = FALSE,
+
           mediation=FALSE, g.nknots=1,
+
           pte.times=NULL, pte.ntimes=NULL,
           pte.nmc=500, pte.boot=FALSE, pte.nboot=2000,
+
```

```
+ pte.boot.nmc=500, pte.integ.type=2)
```

In order to use this function, the user has to provide a dataset (argument data) of the following structure:

```
R> head(data)
```

trialID	trt	statusS	statusT	timeS	timeT	patientID
1	0	1	1	2.217739	9.057946	1
1	0	1	1	1.389263	2.986813	2
1	1	0	1	8.874237	8.874237	3
1	1	1	1	1.809671	3.245388	4
1	0	1	1	2.603604	4.448964	5

The dataset must contain one line per subject and seven columns: one for the subject's identification number (column patientID), for the trial number (trialID), treatment indicator (trt)as well as one for the follow-up

time for the surrogate (timeS) and censoring indicator (statusS) and for the follow-up time for the final endpoint (timeT) and censoring indicator (statusT).

The arguments indicator.zeta and indicator.alpha are used to indicate if one wants to estimate the parameters  $\zeta$  and  $\alpha$  in Model (1). If they are set to 0 then these parameters will not be estimated and assumed to be equal to 1, which means that the random effects will have the same effect on S and T. The parameter frail.base indicates if the user wants to include the trial-level random effects  $u_i$  in the model. If set to 0 then these random effects are not included, and neither will be the parameter  $\alpha$  associated with  $u_i$ . The number of knots used in the M-splines basis for estimating the functions  $\lambda_{0,S}(\cdot)$  and  $\lambda_{0,T}(\cdot)$  can be set through the argument n.knots, with allowed values between 4 and 20 knots.

For the parametric bootstrap used to derive the standard error and confidence interval for the estimated Kendall's  $\tau$ , the argument **nboot.kendall** can be used to fix the number of bootstrap samples to be generated.

The option to include the function  $\gamma(S)$  in Model (1) is given by setting the argument mediation to TRUE. In that case the function  $\gamma(S)$  is estimated using a basis of B-splines whose number of knots is given by the argument g.nknots, which can take any value between 1 and 5 and the function PTE(t) will also be estimated. The timepoints at which this function has to be evaluated can be specified through the argument pte.times. Note that these times should be between 0 and the maximum observed final endpoint times. If one does not want to specify any timepoints, the argument pte.ntimes can be used instead to specify the number of timepoints at which PTE(t) should be evaluated. These points will then be selected evenly on the range of the observed event times. The argument pte.boot is used if we want to compute quantile-based confidence bands of PTE(t)using parametric bootstrap. If set to TRUE, then the number of bootstrap samples to be used can be set with pte.nboot.

Other parameters are mainly pertain to computational details. A complete description of each parameter can be found in the documentation of the package frailtypack available on the CRAN.

The function jointSurroPenal returns an R object of class jointSurroPenal if the argument mediation is set to FALSE and of class jointSurroMed otherwise. In both cases, common R functions such as summary, print and plot can be used as will be illustrated in Section 4.

#### 3.3.2 Function longiPenal

The function longiPenal can be used to investigate surrogacy when the surrogate outcome is a longitudinal biomarker and the final endpoint is a time-to-event (Model (2)). The call to this function is as follows (the values given to each parameters are the default values):

```
R> model <- longiPenal(formula, formula.LongitudinalData,
            data, data.Longi, formula.Binary = FALSE,
+
+
            random, random.Binary = FALSE,
            fixed.Binary = FALSE, GLMlog = FALSE,
            MTP = FALSE, id, intercept = TRUE,
            link = "Random-effects", timevar = FALSE,
            left.censoring = FALSE, n.knots,
            kappa, maxit = 350, hazard = "Splines",
            mediation = FALSE, med.center = NULL, med.trt = NULL,
            init.B, init.Random, init.Eta,
            method.GH = "Standard", seed.MC = 1, n.nodes,
            LIMparam = 1e-3, LIMlogl = 1e-3, LIMderiv = 1e-3,
            print.times = TRUE, med.nmc = 500, pte.times = NULL,
+
            pte.ntimes = NULL, pte.nmc = 500,
            pte.boot=FALSE,pte.nboot=2000)
```

This function requires the specification of two datasets. The first one, specified through the argument data, contains the data regarding the final endpoint T such as the follow-up time for each subject, the censoring indicator, and potential baseline covariates. Note that this dataset requires one line per subject and therefore does not allow for time-dependent covariates to be included. Associated with this dataset is the **formula** wich is a formula object, with the response on the left of a  $\sim$  operator, and the covariates on the right. The response must be a survival object as returned by the **Surv** function of the R **survival** package (THERNEAU, 2024). The variables used in **formula** should be the ones contained in **data**. For the longitudinal part, the repeated measurements data are specified in a separate dataset through the argument **data.Longi**. The specification of the longitudinal submodel is made through

formula.LongitudinalData which is a R formula with the observed biomarker on the left and the different covariates on the right. Both the names for the biomarker and the covariates specified in this formula should correspond to columns in the dataset data.Longi.

Both data and data.Longi should have a column labelled "id" that corresponds to the identificator of each subject in order to link the two datasets, i.e., id=1 in data should corresponds to the same individual with id=1 in data.Longi. Note that for simplicity the variable id should takes values between 1 and  $n_i$  where  $n_i$  is the total number of subjects.

The argument intercept can be used to indicate if one wants to include the fixed intercept  $\beta_0$  in the longitudinal submodel, with default value being TRUE.

The argument timevar is used to specify the timepoints of the repeated measurements in data.Longi for each individual. This variable can be included in formula.LongitudinalData but is not required, a transformation of timevar can be used instead to take into account non linear time evolution. However, in both case a variable timevar must be included in the dataset which contains the measurement times.

The individual-level random effects to be included in the longitudinal submodel are specified through the argument random which must be a vector of characters corresponding to covariates in data.Longi. The character "1" is used to indicate a random intercept. For example if one wants to include a random intercept and a random slope then one should specify random=c("1","timevar") (given that timevar has been included in formula.LongitudinalData).

The baseline hazard function estimation type is chosen via the argument hazard. Possible values are "Splines" and "Splines-per" for flexible hazard functions estimated with M-Splines with respectively equidistant or percentile knots, or "Weibull" to specify a parametric Weibull hazard function. For "Splines" and "Splines-per" the number of knots used is set through the argument n.knots.

The mediation analysis is enabled by setting the argument mediation to TRUE. In that case one should also specify the name of the variable in data that corresponds to the treatment through the argument treatment. Moreover, one should also specify the centers (or trials) to which each subject belongs through the argument centers. This argument takes a character string which must correspond to the name of the variable in data indicating the center/trial of each subject. Note that as the variable id, the variable indicating the center for each subject should take values between 1 and K where K is the total number of centers/trials. If mediation is set to TRUE then the function PTE(t) will be estimated. As for the function jointSurroPenal, one can specify the timepoints at which PTE(t) should be evaluated or the number of timepoints at which it should be evaluated. The argument pte.boot takes values TRUE/FALSE to indicate if the parametric bootstrap estimation of the standard-error of PTE(t) and its confidence bands should be computed. If set to TRUE then the number of bootstrap samples is specified by pte.nboot with a default value of 2000. A complete description of each parameter can be found in the documentation of the package frailtypack available on the CRAN.

The function longiPenal returns a R object of class longiPenal on which the usual R functions summary, print and plot can be applied as will be illustrated in Section 4.

## 4 Illustrations

We illustrate the proposed methods in three applications on cancer data from meta-analyses or multicentric randomized clinical trial. The first application is based on a dataset on ovarian cancer, the second on gastric cancer and the third on colorectal cancer. In the following we assume that the frailtypack package is loaded using the R commands require(frailtypack) or library(frailtypack).

## 4.1 Progression-free survival as a surrogate of overall survival in advanced ovarian cancer: meta-analytic approach

In this first application we are interested in evaluating progression-free survival as a surrogate endpoint for overall survival in advanced ovarian cancer using the classical meta-analytic approach and its two-level validation. The dataset is the dataOvarian which can be loaded from frailtypack using the following command:

## R> data("dataOvarian")

This dataset combines the data of four double-blind randomized clinical trials. These trials investigated the efficacy of cyclophosphamide plus cisplatin versus cyclophosphamide plus adriamycin plus cisplatin in advanced colorectal cancer (OVARIAN CANCER META-ANALYSIS PROJECT, 1991). The structure of the dataset is as follows:

## R> head(dataOvarian)

	patientID	trialID	trt	timeS	statusS	timeT	statusT
1	1	2	0	0.10515873	1	0.1857143	1
2	2	2	0	0.89523809	1	1.4087302	1
3	3	2	0	0.07896825	1	0.1261905	1
4	4	2	1	1.73928571	0	1.7392857	0
5	5	2	0	0.09126984	1	0.1273810	1
6	6	2	1	0.16984127	1	0.2253968	1

The columns patientID and trialID indicate the identifiers of the subject and the trial respectively. The variable trt takes value 0 for cyclophosphamide plus cisplatin and 1 for cyclophosphamide plus adriamycin and cisplatin. The variables timeS and statusS are the follow-up and censoring indicator of the time-to-progression (the surrogate) while timeT and statusT are the follow-up and censoring indicator of the time-to-death (from any cause).

## 4.1.1 Model fitting and surrogacy evaluation

Once the dataset has been loaded, we can call the jointSurroPenal function as follows:

```
R> mod.ovar <- jointSurroPenal(data = dataOvarian, n.knots = 8,
+ indicator.alpha = 0, nb.mc = 500, scale = 1/365)
```

Here we do not specify the option mediation=TRUE (the default value being FALSE), therefore the approach used corresponds to a "classical" meta-analytic approach rather than a mediation approach and is based on Model (1) without inclusion of the function  $\gamma(S)$ .

We specify that the number of knots (inner + boundary) in the M-splines basis for estimating the two baseline hazard functions  $\lambda_{0,S}$  and  $\lambda_{0,T}$  is 8 (n.knots = 8). The argument indicator.alpha = 0 indicates that we don't estimate the parameter  $\alpha$  which will be fixed to 1 throughout the estimation procedure (see Model (1)). The argument nb.mc = 500 specifies that the number of Monte Carlo points used in the approximation of the integral on the trial-level random effects is set to 500. Finally

scale = 1/365 is used to rescale the follow-up times in days (originally expressed in years). The object
mod.ovar belongs to the class jointSurroPenal on which we can apply the R summary function. The
results of the estimation can be simply outputed using the command print(mod.ovar). The base
R function can be used summary to displays estimators of the estimated fixed treatment effects and
surrogacy measures.

R> print(mod.ovar)

```
Estimates for variances parameters of the random effects
         Estimate Std Error
                                 z
                                         Ρ
theta
            6.852
                     0.3781 18.121 < e-10 ***
                     0.0709 25.224 < e-10 ***
zeta
            1.788
gamma
            0.062
                     0.0855 0.724 0.4691
                     0.3375 1.522 0.1279
sigma2_S
            0.514
                     0.9249 1.700 0.08918
sigma2_T
            1.572
sigma_ST
            0.899
                     0.5502 1.634 0.1023
Estimates for the fixed treatment effects
       Estimate Std Error
                               z
                                        Ρ
beta_S
        -0.696
                   0.2239 -3.108 0.001883 **
beta_T
        -1.017
                   0.3824 -2.660 0.007813 **
___
Signif. codes: 0 '***' 0.001 '**' 0.01 '*' 0.05 '.' 0.1 ' ' 1
hazard ratios (HR) and confidence intervals for the fixed treatment effects
       exp(coef) Inf.95.CI Sup.95.CI
beta_S
           0.499
                     0.322
                               0.773
beta_T
           0.362
                     0.171
                               0.765
Surrogacy evaluation criterion
             Level Estimate Std Error Inf.95.CI Sup.95.CI Strength
Ktau
        Individual
                      0.681
                                   ___
                                          0.663
                                                    0.693
R2trial
                      1.000
                                          0.997
                                                    1.003
             Trial
                                0.002
                                                              High
R2.boot
             Trial
                      0.975
                                   ___
                                          0.847
                                                    1.000
                                                              High
___
Correlation strength: <= 0.49 'Low'; ]0.49 - 0.72[ 'Medium'; >= 0.72 'High'
____
The treatment effects on the surrogate endpoint (beta_S)
that can predict a nonzero treatment effect on the true endpoint (beta_T)
belongs to the interval: ]-Inf ; -0.296[ : HR= ]0 ; 0.744[
Surrogate threshold effect (STE) : -0.296 (HR = 0.744 )
Convergence parameters
Penalized marginal log-likelihood = -10892.959
Number of iterations = 22
Smoothing parameters = 60093516.4969293 0.000207706120839778
Number of spline nodes = 8
```

```
LCV = the approximate likelihood cross-validation criterion
```

```
in the semi parametrical case = 9.162
Convergence criteria:
Parameters = 2.198e-06 Likelihood = 8.474e-06 Gradient = 8.65e-10
Estimation based on a combination of
both Gaussian-Hermite quadrature and Monte Carlo integration
```

The first part of the results shows the estimated variance of the individual and trial-level random effects and the power parameters associated with  $\omega_{ij}$  and  $u_i$  in the hazard function of T (respectively  $\alpha$  and  $\zeta$ ). Note that here we only have an estimation for  $\zeta$  since we specified indicator.alpha = 0. These results show a significant variance of the individual-level random effect  $\omega_{ij}$  (variable theta). Since the parameter  $\zeta$  is also significantly different from 0, both S and T are positively correlated at the individual level. On the other hand, the trial-level random effects variance (variable gamma) are not significantly different from 0. The variables sigma2\_S, sigma2\_T and sigma\_ST are respectively the estimations of the variance of  $\nu_{S,i}$ , the variance of  $\nu_{T,i}$  and their covariance.

The second part of the results show the estimated fixed treatment effects, their estimated standard errors and the associated Wald statistics and p-values. There are significant treatment effects on both endpoints, therefore the addition of adriamycin to cyclophosphamide plus cisplatin reduces the risk of the occurrences of progression and death.

The third part of the results shows the hazard-ratios associated with the estimated fixed treatment together with their 95% confidence intervals, with a hazard ratio of 0.499 ([0.322, 0.773]) for the surrogate and 0.362 ([0.171, 0.765]) for the final endpoint.

The fourth part of the results shows the estimated surrogacy measures at the individual and trial level. The variable Ktau is the estimated Kendall's  $\tau$  between the surrogate and the final endpoint with its associated 95% confidence interval. The estimated value of 0.681 suggests a mild association between the two endpoints. The variable R2trial is the estimated  $R_{\text{trial}}^2$  with its estimated standard error (obtained using the delta-method) and its 95% confidence interval while R2.boot obtained using parametric bootstrap. Their values close to 1 suggest a high association between the treatment effects on the surrogate and the final endpoint at the trial-level. Finally these results suggest that the time-to-progression can be considered as a good surrogate of the overall survival in this setting of advanced ovarian cancer.

Additionally, the results give the surrogate threshold effect estimated at -0.296 (associated hazardratio 0.744). This means that in a new trial, the minimal treatment effect on the surrogate to be observed in order to predict a significant treatment effect on the final endpoint is -0.296.

Moreover, the estimated baseline hazard functions  $\lambda_{0,S}$  and  $\lambda_{0,T}$  can be plotted from the mod.ovar object using the R function plot from the following command:

R> plot(mod.ovar, pos.legend = "topleft")



It should be noted that the results in this application have to be interpreted with caution. The broad confidence interval and a point estimate close to 1.0 for  $R_{\text{trial}}^2$  may indicates convergence issues, even if the three convergence criteria (based on the likelihood, its first order derivative and its second order derivative) show that the model converged.

# 4.2 Time-to-relapse as a surrogate of overall survival using proportion of treatment effect in gastric cancer: a mediation approach

The second application is on a meta-analysis on resectable gastric cancer patients investigating the addition of adjuvant chemotherapy after surgery versus surgery alone (PAOLETTI et al., 2010). In this illustration, the final endpoint is the time between randomization and death from any cause while the surrogate is the time-to-relapse, defined as the time between randomization and disease recurrence or occurrence of a second cancer, whichever occurred first. Therefore both endpoints might be right censored due to loss to follow-up and moreover the surrogate endpoint might be censored by the final endpoint. We are interested in estimating the proportion of treatment effect (adjuvant chemotherapy or not) on overall survival that goes through its effect on time-to-relapse.

## 4.2.1 Dataset

As for the first illustration, the dataset gastadj can be loaded directly from frailtypack using the command

```
R> data("gastadj")
```

This dataset contains the data of 3288 patients from 14 randomized clinical trials. Out of these 3288 patients, 1654 were assigned to the control group of no adjuvant chemotherapy, and the remaining 1634 patients were assigned to receive adjuvant chemotherapy. The dataset has the following structure, using the command head(gastadj),

```
R> head(gastadj)
```

trialID	patientID	trt	tin	neT	statusT	tin	ıeS	statusS	
1	1	1	1	463	86	0	463	36	0
2	1	2	1	453	86	0	453	36	0
3	1	3	0	315	51	1	315	51	1
4	1	4	1	48	35	1	43	32	1
5	1	5	0	43	85	1	30	00	1
6	1	6	0	18	37	1	13	37	1

The columns trialID, patientID, trt are the trial, patient and treatment indicator respectively. The variables timeT, timeS are the follow-up times for the final endpoint and surrogate endpoints respectively and statusT, statusS their associated censoring indicator. In this dataset, the variable timeS corresponds to a time-to-progression defined as the earliest between cancer recurrence, occurrence of a second cancer or death. Therefore this endpoint includes death as a composite endpoint which raises questions from a mediation analysis viewpoint since the final endpoint always triggers the surrogate. To circumvent this, we instead analyzed the time-to-relapse (cancer recurrence or second cancer) by censoring them at the time of death. In the dataset this change can be made using the following command,

```
R> gastadj[gastadj$timeS == gastadj$timeT &
+ gastadj$statusS == 1, c("statusS")] <- 0</pre>
```

For practical purposes, and to reduce the computation time, we restrain this illustration on a subset of the original dataset, by selecting 20% of the patients at random.

Moreover, to circumvent some computing issues, we divide the time variable (originally represented in a daily scale) by 365 in the yearly scale. Therefore, the full call for data preparation is

```
R>
    data(gastadj)
    gastadj$timeS <- gastadj$timeS/365</pre>
R>
    gastadj$timeT <- gastadj$timeT/365</pre>
R>
R>
    #"statusS" corresponds now
R> #to a time-to-relapse event
    gastadj[gastadj$timeS == gastadj$timeT &
R.>
    gastadj$statusS == 1, c("statusS")] <- 0</pre>
R>
R>
    # select 20% of the original dataset
    set.seed(1)
R.>
R>
    n <- nrow(gastadj)</pre>
    subset <- gastadj[sort(sample(1:nrow(gastadj),</pre>
R>
+
               round(n*0.2), replace = F)),]
```

## 4.2.2 Model fitting and surrogacy evaluation

The call to the function jointSurroPenal is the following:

```
R> mod.gast<-jointSurroPenal(subset,n.knots = 4,
+ indicator.zeta = 0, indicator.alpha = 0,
+ mediation = TRUE, g.nknots = 1,
+ pte.times = seq(1.5, 2,length.out = 30),
+ pte.nmc = 10000, pte.boot = TRUE, pte.nboot = 1000,
+ pte.boot.nmc = 1000)
```

In this call we set both indicator.zeta and indicator.alpha to 0, therefore the parameters  $\zeta$  and  $\alpha$  in Model (1) are not estimated and assumed to be equal to 1.

Here we specify that mediation = TRUE, therefore the function  $\gamma(S)$  in Model (1) will be estimated using B-Splines. The number of inner knots used in the spline basis is fixed to 1 via the command g.nknots=1. Since we are interested in the mediation analysis setting, we specify that we want the function PTE(t) to be evaluated at 30 timepoints defined by the argument pte.times. The number of Monte-Carlo points used in the approximation of the integral over the random effects in Equation 9 is set to 10000. The use of parametric bootstrap to derive estimated standard-errors and confidence bands for PTE(t) is given by pte.boot=TRUE where we also specify that we want this bootstrap to be based on 1000 sampling via rt.nboot=1000. Finally, for illustration purposes and to reduce computation time, we also set the number of Monte Carlo points used for each bootstrap sample to 1000. However, in practice this number should be the same as for the estimation of PTE(t). The object mod.gast has R class jointSurroMed, and we can apply the summary function to display the results.

R> summary(mod.gast)

Results of a joint surrogate mediation model using a penalized likelihood on the baseline hazard functions.

Estimates for variances parameters of the random effects

	Estimate	Std Error	z	Р					
theta	5.061	0.5798	8.729	< e-10	***				
gamma	2.143	0.8059	2.659	0.007837	**				
sigma2_S	0.551	0.3529	1.561	0.1184					
sigma2_T	0.601	0.3990	1.507	0.1317					
sigma_ST	0.575	0.3568	1.613	0.1068					
Estimate	s for the	fixed trea	atment	effects					
E:	stimate St	d Error	Z	Р					
beta_S	-0.404	0.3216 -:	1.257 (	0.2086					
beta_T	-0.280	0.3384 -0	0.827 (	0.4083					
Signif.	codes: 0	·*** 0.00	01 '**	° 0.01 '*	0.05	'.' 0.1 '	'1		
Hazard ra	atios (HR)	and conf:	idence	interval	s for t	the fixed	treatment e	ffects	
e	xp(coef) ]	Inf.95.CI S	Sup.95	.CI					
beta_S	0.667	0.355	1.2	253					
beta_T	0.756	0.389	1.4	167					
	_								
Individual and trial level associations									
	Level	L Estimate	Std E	rror Inf.9	95.CI S	Sup.95.CI	Strength		
Ktau :	Individua	L 0.618		(	0.574	0.660			
R2trial	Tria	L 0.999	0	.013 (	0.974	1.025	High		
R2.boot	Tria	L 0.926		(	0.494	1.000	High		
Correlation strength: <= 0.49 'Low'; ]0.49 - 0.72[ 'Medium'; >= 0.72 'High'									

```
Estimated function g at 3 times of occurence of the surrogate
    Time
             g
                       CI.95
1 4.167 3.088 [2.567;3.609]
2 8.341 2.661 [1.483;3.838]
3 12.514 2.600 [0.185;5.015]
Estimated function PTE(t), natural direct, indirect and total effect
at 3 time points
   Time
          PTE
                   CI.95.PTE
1 1.655 0.281 [-0.292;0.457]
2 1.828 0.273 [-0.003;0.573]
3 2.000 0.042 [-0.308;0.444]
   Time
            ΤE
                    CI.95.TE
1 1.655
        0.023 [0.015;0.031]
2 1.828
        0.027 [0.019;0.038]
3 2.000
        0.026 [0.017;0.037]
           NDE
                   CI.95.NDE
   Time
1 1.655
        0.017 [0.012;0.029]
2 1.828
        0.020 [0.011;0.029]
3 2.000 0.025 [0.014;0.034]
   Time
           NIE
                    CI.95.NIE
1 1.655 0.007 [-0.005;0.012]
2 1.828
        0.008
                    [0;0.017]
3 2.000 0.001 [-0.007;0.013]
Convergence parameters
Penalized marginal log-likelihood = -1362.853
Number of iterations = 14
LCV = the approximate likelihood cross-validation criterion
      in the semi parametrical case
                                        = 2.106
Convergence criteria:
  parameters = 0.0004349 likelihood = 0.0004285 gradient = 5.591e-07
```

As in the first illustration, we first have the estimation of the random effects variances. The parameters **theta** and **gamma** (the variances of  $\omega_{ij}$  and  $u_i$  in Model (1) respectively) are significantly different from 0; there is an association between S and T at the individual-level (through  $\omega_{ij}$ ) and trial-level  $(u_i)$ . However, the variances of  $\nu_S$  and  $\nu_T$  associated with the heterogeneity of the treatment effects between trials are not significantly different from 0.

The estimated fixed treatment effect on the surrogate and the final endpoint are respectively -0.404 and -0.280. Given their large estimated standard-error, these effects are not significant.

Regarding the association measures of surrogacy we have an estimated Kendall's  $\tau$  of 0.618 with a 95% confidence interval [0.574, 0.660] which suggests a poor individual-level surrogacy. At the triallevel the estimated  $R_{\text{trial}}^2$  is 0.999 and its 95% confidence interval is [0.974, 1.025]. The bootstrapped estimation and confidence interval are 0.926 and [0.494, 1.000], which suggest not enough evidence to support a good trial-level surrogacy.

The next part of the results shows the value of the estimated function  $\gamma(\cdot)$  at three timepoints. We can see that for the three times the estimated values are significantly different from 0, which suggest that there is a direct link between the occurrence of the surrogate S and the risk of occurrence of T. Moreover the estimated function  $\gamma(S)$  being positive translates as an increased risk of occurrence of T once the surrogate occurs.

The next part of the results displays the estimated values of the function PTE(t) at the same three timepoints, as well as the estimated total treatment effect, TTE(t), natural indirect and direct effects, NIE(t) and NDE(t).

First, for PTE(t), we can see that for the three timepoints, the estimated values of PTE(t) are small, with values ranging from 0.281 to 0.042, with their confidence interval containing the value 0. This suggest a poor proportion of treatment effect. Moreover, the wide confidence intervals are due to a total treatment effect, TTE(t), very close to 0, therefore PTE(t) defined as the ratio of NIE(t) over TTE(t) may be extremely instable if  $TTE(t) \approx 0$ , resulting in the wide confidence interval. Both the direct effect, NDE(t), and indirect effect, NDE(t), are also very close to 0. The mediation measures of surrogacy, essentially PTE(t) and associated NIE(t) and NDE(t), are inherently time-dependent. Therefore a graphical representation might be of interest when investigating surrogacy through theses measures. Especially the plot function can be applied to the object mod.gast to display the estimated results.

#### R> plot(mod.gast, type.plot = "Hazard", plot.mediation= "All")













We first have the estimated baseline survival functions associated with the baseline hazard function  $\hat{\lambda}_{0,S}(t)$  and  $\hat{\lambda}_{0,T}(t)$  and their 95% confidence bands through the command type.plot = "Survival". Another option is to set type.plot = "Hazard" to plot the  $\hat{\lambda}_{0,S}(t)$  and  $\hat{\lambda}_{0,T}(t)$ . The argument plot.mediation can takes the values "g", "effects", "pte" or "All" depending if one want to plot only  $\gamma(\cdot)$ , the natural effects (NIE(t),NDE(t) and TTE(t)), the PTE(t) or all at the same time.

From these figures we see that the direct effect is indeed not significant, while the indirect effect is. However, even if the direct effect is not significantly different from 0, most of its confidence bands contains negative values therefore the NIE and NDE are in opposite direction. Therefore we have  $0 \leq \text{TE} \leq \text{NIE}$  and thus  $\text{PTE} \geq 1$ . Moreover, the large confidence interval of PTE can be explained by the confidence bands of TTE(t) containing values very close to 0, hence a large instability of PTE(t).

Finally, there is not enough evidence, for both the association and mediation approaches to suggest good surrogacy in this context. A limitation is the small total treatment effect which makes difficult the interpretation of the PTE(t) since it can be very unstable in that case.

## 4.3 Tumor size as a surrogate biomarker of overall survival in colorectal cancer: a mediation approach

In this third application we are interested in evaluating the tumor size evolution over time as a surrogate of the overall surival in colorectal cancer. Since the tumor size evolution is a longitudinal biomarker we will base the analysis on the function longiPenal.

We will use a dataset containing 150 patients randomly selected from the FFCD 2000-05 multicenter phase III clinical trial (DUCREUX et al., 2011). This trial originally included 410 patients with metastatic colorectal cancer randomized into two treatment strategies: combination and sequential chemotherapy. The dataset contains times of observed appearances of new lesions censored by a terminal event (death) with some baseline characteristics.

Because the available dataset does not contain the identificator of the center of the patients and for computational purposes, we illustrate the approach without taking into account the multi-centric nature of the data. The data are actually composed of two datasets, one for the survival part and another containing the repeated measurements of tumor sizes.

## 4.3.1 Dataset

As for the two previous illustrations these two datasets can be loaded from frailtypack.

```
R> data(colorectal)
```

```
R> data(colorectalLongi, package = "frailtypack")
```

The dataset **colorectal** contains several observations per subject, one for each new lesions in addition to a follow-up time and a censoring indicator for death.

Therefore we only want to retrieve the last observation for a subject. In this dataset the variable **new.lesions** takes the value 1 if a new lesion is record and 0 otherwise. Therefore if a subject has  $n_i$  observations, the observations  $1, \ldots, n_{i-1}$  all have the status **new.lesions** equals to 1 (since the repeated follow-up are based on the appearance of new lesions). Hence, the last observation for each subject can be taken as the only one for which **new.lesions** equals 0:

```
R> colorectalSurv <- subset(colorectal, new.lesions == 0)</pre>
```

In the dataset the variable treatment takes the value "S" for "sequential" and "C" for "combined", for interpretability we simply make this variable binary 0/1,

```
R> colorectalSurv$treatment <- sapply(colorectalSurv$treatment,
+ function(t) ifelse(t == "S", 1, 0))
```

```
R> colorectalLongi$treatment <- sapply(colorectalLongi$treatment,</pre>
```

```
+ function(t) ifelse(t == "S", 1, 0))
```

To keep the illustration simple we only adjust on the variable age as a categorical variable: <60 years, 60-69 years or >69 years.

#### 4.3.2 Model fitting and surrogacy evaluation

The call to the function is:

```
mod.col = longiPenal(Surv(time1, state) ~ age + treatment,
R>
              tumor.size ~ age + year*treatment,
+
              data = colorectalSurv, data.Longi = colorectalLongi,
+
              random = c("1", "year"), id = "id",
+
+
              link = "Current-level", timevar = "year",
+
              method.GH = "Pseudo-adaptive",
+
              mediation = TRUE,
+
              med.trt = colorectalSurv$treatment,
              med.center = NULL,
              n.knots = 7, kappa = 2,
+
              pte.times = seq(1,2,length.out = 30),
+
              pte.boot = TRUE, pte.nboot = 2000,
+
              pte.nmc = 1000)
```

In this call we fit a model using a "Current-level" link function between the longitudinal biomarker and the final endpoint. We specify a random slope and intercept in the longitudinal submodel. The arguments n.knots and kappa specify the number of knots and the penalization term related to the splines baseline hazard function; The argument mediation = TRUE indicates that we want to compute the natural direct and indirect effects as well as the proportion of treatment effect, PTE(t). We require that this function to be evaluated at 30 timepoints between 1 and 2 through the argument pte.times. Moreover, we also require that the bootstrap standard error and confidence interval for PTE(t) computed using 2000 samples. Finally, pte.nmc specify the number of Monte Carlo sample to be used for integrating over the random effects distributions for the computation of the mediation-related quantities such as the PTE(t) and the natural direct and indirect effects.

The result can be displayed by applying the R function print to the object mod.col.

```
R> print(mod.col)
```

```
Call:
```

```
longiPenal(formula = Surv(time1, state) ~ age + treatment,
  formula.LongitudinalData = tumor.size ~
  age + year * treatment, data = colorectalSurv,
  data.Longi = colorectalLongi, random = c("1", "year"),
  id = "id", link = "Current-level",
  timevar = "year", n.knots = 7, kappa = 2,
  mediation = TRUE, med.center = NULL,
  med.trt = colorectalSurv$treatment,
  method.GH = "Pseudo-adaptive",
  pte.times = seq(1, 2, length.out = 30),
  pte.nmc = 1000, pte.boot = TRUE,
  pte.nboot = 2000)
```

Joint Model for Longitudinal Data and a Terminal Event Parameter estimates using a Penalized Likelihood on the hazard function Proportion of treatment effect estimated using mediation analysis

```
Longitudinal outcome:
```

\_\_\_\_\_

	coef	SE coef (H)	SE coef (HIH)	Z	р
Intercept	3.137931	0.162309	0.162293	19.333100	<1e-16
age60-69 years	0.018671	0.161011	0.161005	0.115963	9.0768e-01
age>69 years	-0.199278	0.132941	0.132937	-1.498991	1.3388e-01
year	-0.856672	0.119570	0.119537	-7.164634	7.7993e-13
treatment	-0.014291	0.210141	0.210140	-0.068007	9.4578e-01
year:treatment	0.573562	0.179795	0.179791	3.190090	1.4223e-03

chisq df global p age 3.64584 2 0.162

```
Terminal event:
```

coef exp(coef) SE coef (H) SE coef (HIH)zpage60-69 years-0.1893190.8275220.2388210.237460-0.7927254.2794e-01age>69 years0.0432711.0442210.2216630.2191580.1952138.4523e-01

```
treatment
              -0.073594 0.929049
                                     0.199693
                                                   0.199502 -0.368536 7.1247e-01
      chisq df global p
age 0.984705 2
                 0.611
Components of Random-effects covariance matrix B1:
Intercept 2.047206 -0.486161
          -0.486161 0.733352
year
Association parameters:
                 coef
                              SE
                                      z
                                                 р
Current level 0.340028 0.0772822 4.39982 1.0834e-05
Residual standard error: 0.928261 (SE (H): 0.025609 )
Mediation analysis:
_____
Estimated PTE, natural direct, indirect and total effect at 5 time points
                                                  CI.95.TE
   Time
           PTE
                        CI.95.PTE
                                       ΤE
                                                              NDE
                                                                         CI.95.NDE
1 1.1724 0.4808 [-9.9605;11.7879] -0.0218 [-0.0865;0.0738] 0.0119 [-0.0666;0.1168]
2 1.3793 0.4861 [-13.6501;11.2626] -0.0120 [-0.0865;0.074] 0.0158 [-0.0654;0.1165]
3 1.5862 0.4959 [-12.3904;16.3048] -0.0182 [-0.0868;0.0757] 0.0138 [-0.0652;0.1156]
4 1.7931 0.5212 [-9.9141;14.5458] -0.0201 [-0.0858;0.0739] 0.0167 [-0.0637;0.1186]
5 2.0000 0.8399 [-19.2805;14.5575] -0.0101 [-0.0376;0.0269] 0.0123 [-0.0276;0.0653]
      NIE
                 CI.95.NIE
1 -0.0337 [-0.0587;-0.0113]
2 -0.0278 [-0.0579;-0.0115]
3 -0.0321 [-0.0572;-0.0119]
4 -0.0367 [-0.0591;-0.0105]
5 -0.0224 [-0.0445;-0.0072]
      penalized marginal log-likelihood = -1668.92
      Convergence criteria:
      parameters = 1.37e-05 likelihood = 0.000256 gradient = 1.34e-06
     LCV = the approximate likelihood cross-validation criterion
            in the semi parametrical case
                                             = 1.59769
     n= 150
      n repeated measurements= 906
```

```
number of iterations: 14
```

n events= 121

Exact number of knots used: 7 Value of the smoothing parameter: 2 Gaussian quadrature method: Pseudo-adaptive with 9 nodes

From these results we see a significant effect of the treatment-time interaction on the surrogate (through the slope), while the estimated  $\beta_{Z,T}$  is not significantly different from 0. The individual random effects suggest a heterogeneity at baseline of the tumor size value. Moreover the estimated covariance matrix suggest no treatment heterogeneity across the trial, which is expected due to randomization (of the trials). Moreover the association between the surrogate and the final endpoint (through the **Current-level** parameter) is significantly different from 0.

The results regarding the mediation analysis are displayed in the Mediation analysis section of the printed results. It shows the estimated PTE, total effect (TE), natural direct effect (NDE) and natural indirect effect (NIE) at several times. While in the function call we specified these quantities to be computed at 30 time points, the print call returns by default only 5 of them for readability. From these result we see that PTE(t) ranges from 0.480 for t close to 1 to 0.840 for t = 2. However, the estimated total effect (TE) is very close to 0 at each time and its confidence interval contains 0 at each time. Therefore, the confidence intervals for PTE(t) is very broad and no meaningful interpretation of surrogacy can be made in this case.

The estimated baseline hazard function  $\hat{\lambda}_{0,T}(t)$ , PTE(t) and estimated natural effects can be plotted using the R function plot.

## R> plot(mod.col, plot.mediation = "All", conf.bands = TRUE)





As previously stated, regarding the mediation measures, we can see that neither the direct effect, NDE(t), indirect effect NIE(t) nor the total effect, TTE(t) are significant, which results in a very large confidence interval for the PTE(t).

As we can see, the confidence bands for the estimated PTE(t) are very wide. This is explained by the absence of treatment effect on the final endpoint; therefore  $TTE(t) \approx 0$  which results in very high uncertainty regarding PTE(t). As such, it is impossible to conclude regarding the surrogacy, since the absence of treatment effect on the final endpoint renders the search for surrogate endpoints pointless. The validation of surrogates endpoint should only be made for treatments that have proved their efficacy regarding the final endpoint. In this application the low number of patients (150) is a clear limitation.

## 5 Discussion

In this paper we presented new implementations of surrogate endpoint validation based on joint models that combines meta-analytic data and mediation analysis. These joint models have been implemented in the R package frailtypack. These models combine the two main approaches that have been developed in the statistical literature for surrogate endpoint validation: the meta-analytic approach and the causal mediation analysis approach.

To achieve a shorter computation time, the core of these functions were developed in Fortran and support multithreading through OpenMP. This parallelization takes place at the numerical approximation

of the integral over the random-effects where the iterations (either in a Monte Carlo or quadrature approach) are dispatched between the available threads.

Numerical issues can happen with the estimation of these complex models, especially when computing the likelihood which requires computing integrals over the random effects (both individual and trial level). These integrals do not have closed-form solutions and therefore need to be numerically approximated. Two main approaches for carrying out these approximations can be used, either by using Monte Carlo sampling or Gauss-Hermite quadrature rule. Based on simulations results, it appears that better numerical approximation and convergence of the maximization algorithm is achieved when a Monte-Carlo approach is used to integrate over the trial-level random effects and a Gauss-Hermite rule is used for the integral over the individual-level random effects. The latter can be further improved by using pseudo-adaptive quadrature in which the nodes in the quadrature are chosen to properly recover the scale and shape of the integrand (RIZOPOULOS, 2012a).

Another computational issue concerns specifically Model (2). The likelihood of this model requires computing the product of the individual-likelihoods  $\prod_{j=1}^{n_i} L_{ij}$  for all the patients in trial *i*. Numerical instabilities can occur if  $n_i$  is large and/or if the number of observations per subject is large. If all individual likelihoods are small, say  $L_{ij} \approx 10^{-3}$ , and if  $n_i$  is large,  $n_i \approx 200$  as can be the case for clinical trials, then the product will result in a numerical underflow and rounded to 0. One possible way around is to use a large constant, M, and multiply each individual likelihood by M so that there is no longer a numerical underflow. Since M is a constant it can then be easily taken out of the integral and substracted (when taking the log of this integral). However, in an iterative maximization algorithm, Mmay be suited for the first iterations but as the vector of parameter is updated, so will be the "scale" of the individual-likelihoods  $L_{ij}$  which depend on the parameters. Therefore  $ML_{ij}$  may be too large at a given iteration which can also result in numerical issues (numerical overflow this time). One possibility is to also update to value of M at each iteration so that it keeps track of the scale of the individual likelihoods.

Regarding the individual surrogacy measure (the Kendall's  $\tau$ ), the introduction of a direct effect of the surrogate on the final endpoint creates a difficulty regarding both its definition and computation since this link influences the association between the two endpoints and therefore must be taken into account. For example, in Model (1), the Kendall's without a direct link between S and T (i.e. without the function  $\gamma(S)$ ), is given by Equation (7) which only requires integrating over the distribution of the random effects while the more general  $\tau$  in the presence of  $\gamma(S)$  is given by Equation (6) and requires more complex integration over both the distribution of S and the distribution of the random effects. For the trial-level association measure,  $R_{\text{trial}}^2$ , this issue does not occur since the trial-level random effects take into account all the association between the treatment effects on the surrogate and the final endpoint.

For now the jointSurroPenal function does not allow adjustment on covariates beside the treatment itself, and the surrogacy measures (especially the Kendall's  $\tau$  and the PTE(t)) are defined and computed in a somewhat "covariate-free" manner. Further developments will allow the adjustment on potential covariates in the model and the computation of these surrogacy measures conditionally to a given set of covariates as well as at a marginal (populational) level (EMURA et al., 2021). Adjustment on covariates is already possible in the longiPenal function. However it should be noted that computing a marginal measure averaged over the distribution of the covariates can significantly increase the computation time in the presence of continuous variables. Indeed, marginalization in the case of categorical covariates only requires to compute a  $\tau$  or PTE(t) for each possible group and then averaging them (and weighting by the proportion of each group in the dataset). On the other hand, marginalization in the presence of a continuous covariates would require computing these measures for each observed values of the covariate in the dataset (i.e. for each individual) which can significantly increase the computation time.

Unlike the meta-analytic approach, the mediation analysis does not require, *per se*, the use of metaanalytic data. The combination of meta-analytic data and mediation analysis allows broader generalisation of the results by introducing heterogeneity in the data. If one only has access to single-trial data, a possibility is to use different clustering units instead of "trials", such as "institution" in multicentric studies. Even if our proposed approaches were developed within a meta-analytic setting which is more appropriate for surrogate validation, a further development would be to run a mediation analysis without the requirement of meta-analytic or clustered data (which would yield a simpler model). However, in that case only the individual-level association in addition to the proportion of treatment effect would be available since the trial-level association would not be identifiable.

We want to point out that in a perspective of surrogate validation, there is no acknowledged threshold yet for the surrogacy measures, especially the proportion of treatment effect, above which a surrogate would be claimed validated. Such threshold warrants more investigation in order to give a clear decision rule for the clinicians and statisticians.

Finally, further developments of the frailtypack package will concern the extension of the proposed functions to validate surrogate endpoints. In order to improve the flexibility of the proposed approaches, other options for the type of surrogate or final endpoint will be proposed, for example in the case of a binary final endpoint.

## References

- ALONSO, A. et al. (2016). Applied surrogate endpoint evaluation methods with SAS and R. CRC Press New York.
- BURZYKOWSKI, T. and M. BUYSE (2006). Surrogate threshold effect: an alternative measure for metaanalytic surrogate endpoint validation. *Pharmaceutical Statistics: The Journal of Applied Statistics* in the Pharmaceutical Industry 5, 173–186.
- BURZYKOWSKI, T., M. BUYSE, and G. MOLENBERGHS (2005). The evaluation of surrogate endpoints. Springer.
- BUYSE, M. et al. (2000). The validation of surrogate endpoints in meta-analyses of randomized experiments. *Biostatistics* **1**, 49–67.
- DANIELS, M. J. and M. D. HUGHES (1997). Meta-analysis for the evaluation of potential surrogate markers. *Statistics in medicine* 16, 1965–1982.
- DUCREUX, M. et al. (2011). Sequential versus combination chemotherapy for the treatment of advanced colorectal cancer (FFCD 2000–05): an open-label, randomised, phase 3 trial. *The lancet oncology* 12, 1032–1044.
- EMURA, T., C. L. SOFEU, and V. RONDEAU (2021). Conditional copula models for correlated survival endpoints: Individual patient data meta-analysis of randomized controlled trials. *Statistical Methods* in Medical Research **30**, 2634–2650.

- FRANGAKIS, C. E. and D. B. RUBIN (2002). Principal stratification in causal inference. *Biometrics* 58, 21–29.
- FREEDMAN, L. S., B. I. GRAUBARD, and A. SCHATZKIN (1992). Statistical validation of intermediate endpoints for chronic diseases. *Statistics in medicine* 11, 167–178.
- HERNÁN, M. A. (2010). The hazards of hazard ratios. Epidemiology (Cambridge, Mass.) 21, 13.
- HOLLAND, P. W. (1986). Statistics and causal inference. Journal of the American statistical Association 81, 945–960.
- IMAI, K., L. KEELE, and T. YAMAMOTO (2010). Identification, inference and sensitivity analysis for causal mediation effects. *Statistical science* **25**, 51–71.
- JOFFE, M. M. and T. GREENE (2009). Related causal frameworks for surrogate outcomes. *Biometrics* **65**, 530–538.
- JOLY, P., D. COMMENGES, and L. LETENNEUR (1998). A penalized likelihood approach for arbitrarily censored and truncated data: application to age-specific incidence of dementia. *Biometrics*, 185–194.
- LE COËNT, Q., C. LEGRAND, and V. RONDEAU (Nov. 2022). Time-to-event surrogate endpoint validation using mediation analysis and meta-analytic data. *Biostatistics*. kxac044.
- MARQUARDT, D. W. (1963). An algorithm for least-squares estimation of nonlinear parameters. *Journal* of the society for Industrial and Applied Mathematics **11**, 431–441.
- OVARIAN CANCER META-ANALYSIS PROJECT (1991). Cyclophosphamide plus cisplatin versus cyclophosphamide, doxorubicin, and cisplatin chemotherapy of ovarian carcinoma: a meta-analysis. J Clin Oncol 9, 1668–74.
- PAOLETTI, X. et al. (2010). Benefit of adjuvant chemotherapy for resectable gastric cancer: a metaanalysis. Jama 303, 1729–1737.
- PARAST, L. (2021a). Rsurrogate: Robust Estimation of the Proportion of Treatment Effect Explained by Surrogate Marker Information. R package version 3.1.
- PARAST, L. (2021b). SurrogateOutcome: Estimation of the Proportion of Treatment Effect Explained by Surrogate Outcome Information. R package version 1.1.
- PARAST, L. and D. AGNIEL (2022). longsurr: Longitudinal Surrogate Marker Analysis. R package version 1.0.
- PARAST, L., T. CAI, and L. TIAN (2017). Evaluating surrogate marker information using censored data. Statistics in medicine 36, 1767–1782.
- PRENTICE, R. L. (1989). Surrogate endpoints in clinical trials: definition and operational criteria. Statistics in medicine 8, 431–440.
- RIZOPOULOS, D. (2012a). Fast fitting of joint models for longitudinal and event time data using a pseudo-adaptive Gaussian quadrature rule. Computational Statistics & Data Analysis 56, 491–501.
- RIZOPOULOS, D. (2012b). Joint models for longitudinal and time-to-event data: With applications in R. CRC press.

- ROBINS, J. (1986). A new approach to causal inference in mortality studies with a sustained exposure period—application to control of the healthy worker survivor effect. *Mathematical modelling* 7, 1393– 1512.
- RONDEAU, V. and J. R. GONZALEZ (2005). Frailtypack: A computer program for the analysis of correlated failure time data using penalized likelihood estimation. *Computer Methods and Programs in Biomedicine* 80, 154–164.
- RONDEAU, V., S. MATHOULIN-PELISSIER, et al. (2007). Joint frailty models for recurring events and death using maximum penalized likelihood estimation: application on cancer events. *Biostatistics* 8, 708–721.
- ROSENBAUM, P. R. (1984). The consequences of adjustment for a concomitant variable that has been affected by the treatment. *Journal of the Royal Statistical Society: Series A (General)* **147**, 656–666.
- SOFEU, C. L., T. EMURA, and V. RONDEAU (2019). One-step validation method for surrogate endpoints using data from multiple randomized cancer clinical trials with failure-time endpoints. *Statistics in medicine* 38, 2928–2942.
- THERNEAU, T. M. (2024). A Package for Survival Analysis in R. R package version 3.7-0.
- VAN DER ELST, W. et al. (2022). Surrogate: Evaluation of Surrogate Endpoints in Clinical Trials. R package version 2.4.
- VANDENBERGHE, S. et al. (2018). Surrogate marker analysis in cancer clinical trials through time-toevent mediation techniques. *Statistical methods in medical research* 27, 3367–3385.
- WANG, W. and M. T. WELLS (2000). Estimation of Kendall's tau under censoring. Statistica Sinica 10, 1199–1215.
- WEIR, I. R., J. R. RIDER, and L. TRINQUART (2022). Counterfactual mediation analysis in the multistate model framework for surrogate and clinical time-to-event outcomes in randomized controlled trials. *Pharmaceutical Statistics* 21, 163–175.
- ZHENG, C. and L. LIU (2021). Quantifying direct and indirect effect for longitudinal mediator and survival outcome using joint modeling approach. *Biometrics* 78, 1233–1243.

## Acknowledgements

Q. Le Coënt and C. Legrand acknowledge the support of the ARC project IMAL (grant 20/25-107) financed by the Wallonia-Brussels Federation and granted by the Académie universitaire Louvain.